NEW YORK, NY / ACCESSWIRE / June 13, 2018 / U.S. markets were relatively quiet following the summit between President Donald Trump and North Korean leader Kim Jong Un in Singapore. The Dow Jones Industrial Average declined 0.01 percent to close at 25,320.73, while the S&P 500 Index rose 0.17 percent to close at 2,786.85. The Nasdaq Composite Index gained 0.57 percent to close at 7,703.79. On Tuesday, President Trump and North Korean leader Kim Jong Un signed an agreement pledging to creating a "peace regime" on the Korean peninsula.
"It is a relatively quiet day because investors are reluctant to make any big bets ahead of two central bank meetings," said Mark Kepner, managing director of sales and trading at Themis Trading, according to MarketWatch.
RDI Initiates Coverage on:
Alnylam Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Alnylam Pharmaceuticals' stock jumped 5.86% Tuesday, to close the day at $105.91. The stock recorded a trading volume of 811,352 shares, which was below its three months average volume of 1,064,539 shares. In the last year, Alnylam Pharmaceuticals' shares have traded in a range of 70.76 - 153.99. The share price has gained 49.67% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $98.19 is below its 200-day moving average of $117.37. Shares of Alnylam Pharmaceuticals have gained roughly 4.95 percent in the past month and are down 16.64 percent year-to-date.
Access RDI's Alnylam Pharmaceuticals, Inc. Research Report at:
On Tuesday, shares of Intercept Pharmaceuticals recorded a trading volume of 736,284 shares, which was above the three months average volume of 688,376 shares. The stock ended the day 5.82% higher at $80.56. The share price has fallen 40.59% from its 52 week high with a 52 week trading range of 51.05 - 135.59. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $70.93 is above its 200-day moving average of $64.26. Shares of Intercept Pharmaceuticals have gained roughly 13.46 percent in the past month and are up 37.90 percent year-to-date.
Access RDI's Intercept Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.